Results
1 -
10 of
23Kubas Holger, Meyer Udo, Hechenberger Mirko, Klein Kai-Uwe, Plitt Patrick, Zemribo Ronalds, Spexgoor Harm W., van Assema Sander G.A., Abel Ulrich.
Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators, Bioorganic & Medicinal Chemistry Letters, 2013 mGlu5 Receptors in Parkinson?s Disease and MPTP-Lesioned Monkeys: Behavior and Brain Molecular Correlates, mGLU Receptors Glutamate Receptors and Levodopa-Induced Dyskinesia, Levodopa-Induced Dyskinesia in Parkinson's Disease Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications, Journal of Neural Transmission Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinsonu2019s Disease, CNS Drugs Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study, Advances in Therapy Molecular medicine of fragile X syndrome: based on known molecular mechanisms, World Journal of Pediatrics Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma, Analytical and Bioanalytical Chemistry The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro, BMC Medical Genetics Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant, Psychopharmacology